BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 22652401)

  • 1. Calcineurin B subunit triggers innate immunity and acts as a novel Engerix-B HBV vaccine adjuvant.
    Hu M; Su Z; Yin Y; Li J; Wei Q
    Vaccine; 2012 Jul; 30(32):4719-27. PubMed ID: 22652401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The calcineurin B subunit (CnB) is a new ligand of integrin αM that mediates CnB-induced Apo2L/TRAIL expression in macrophages.
    Liu L; Su Z; Xin S; Cheng J; Li J; Xu L; Wei Q
    J Immunol; 2012 Jan; 188(1):238-47. PubMed ID: 22116828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin subunit B activates dendritic cells and acts as a cancer vaccine adjuvant.
    Li J; Guo J; Su Z; Hu M; Liu W; Wei Q
    Int Immunol; 2011 May; 23(5):327-34. PubMed ID: 21447603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcineurin subunit B is an immunostimulatory protein and acts as a vaccine adjuvant inducing protective cellular and humoral responses against pneumococcal infection.
    Li J; Hu M; Guo J; Su Z; Wei Q
    Immunol Lett; 2011 Oct; 140(1-2):52-8. PubMed ID: 21722668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcineurin subunit B is not an effective adjuvant when combined with a novel HBV protein particle vaccine].
    Chuai X; Chen H; Wang W; Deng Y; Ruan L; Tan WJ
    Bing Du Xue Bao; 2014 Sep; 30(5):554-60. PubMed ID: 25562966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of different adjuvants on immunogenicity of the HBV particle vaccine containing the S + preS1 fusion antigen in Balb/C mice].
    Chen H; Deng Y; Tan W; Wang W; Yin X; Guan J; Wang W; Ruan L
    Sheng Wu Gong Cheng Xue Bao; 2010 Jan; 26(1):74-8. PubMed ID: 20353095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole recombinant Hansenula polymorpha expressing hepatitis B virus surface antigen (yeast-HBsAg) induces potent HBsAg-specific Th1 and Th2 immune responses.
    Bian G; Cheng Y; Wang Z; Hu Y; Zhang X; Wu M; Chen Z; Shi B; Sun S; Shen Y; Chen EJ; Yao X; Wen Y; Yuan Z
    Vaccine; 2009 Dec; 28(1):187-94. PubMed ID: 19789093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platycodin D is a potent adjuvant of specific cellular and humoral immune responses against recombinant hepatitis B antigen.
    Xie Y; Sun HX; Li D
    Vaccine; 2009 Jan; 27(5):757-64. PubMed ID: 19041358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
    Mutwiri G; Benjamin P; Soita H; Babiuk LA
    Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.
    Shen E; Li L; Li L; Feng L; Lu L; Yao Z; Lin H; Wu C
    Cell Mol Immunol; 2007 Apr; 4(2):113-20. PubMed ID: 17484805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes.
    Chow YH; Chiang BL; Lee YL; Chi WK; Lin WC; Chen YT; Tao MH
    J Immunol; 1998 Feb; 160(3):1320-9. PubMed ID: 9570550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination.
    Mizrahi M; Lalazar G; Ben Ya'acov A; Livovsky DM; Horowitz Y; Zolotarov L; Adler R; Shouval D; Ilan Y
    Vaccine; 2008 May; 26(21):2589-95. PubMed ID: 18423947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immune response to HBsAg is enhanced by beta-glucan oligosaccharide containing an alpha-(1-->3)-linked bond and biased towards M2/Th2.
    Dong SF; Chen JM; Zhang W; Sun SH; Wang J; Gu JX; Boraschi D; Qu D
    Int Immunopharmacol; 2007 Jun; 7(6):725-33. PubMed ID: 17466906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
    Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
    J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine.
    Zhang W; Han L; Lin C; Wang H; Pang X; Li L; Gao P; Lin H; Gong X; Tang Y; Ma J; Zhang H; Wang C; Yang P; Li H; Sun M; He X
    Vaccine; 2011 Aug; 29(37):6276-82. PubMed ID: 21722684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral immunization with a live recombinant attenuated Salmonella typhimurium protects mice against Toxoplasma gondii.
    Cong H; Gu QM; Jiang Y; He SY; Zhou HY; Yang TT; Li Y; Zhao QL
    Parasite Immunol; 2005; 27(1-2):29-35. PubMed ID: 15813720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B virus vaccine in lymphoproliferative disorders: a prospective randomized study evaluating the efficacy of granulocyte-macrophage colony stimulating factor as a vaccine adjuvant.
    Yağci M; Acar K; Sucak GT; Yamaç K; Haznedar R
    Eur J Haematol; 2007 Oct; 79(4):292-6. PubMed ID: 17655695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine.
    Fakharzadeh S; Kalanaky S; Hafizi M; Goya MM; Masoumi Z; Namaki S; Shakeri N; Abbasi M; Mahdavi M; Nazaran MH
    Vaccine; 2013 May; 31(22):2591-7. PubMed ID: 23583463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
    Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
    FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
    Vasilakos JP; Smith RM; Gibson SJ; Lindh JM; Pederson LK; Reiter MJ; Smith MH; Tomai MA
    Cell Immunol; 2000 Aug; 204(1):64-74. PubMed ID: 11006019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.